What to Expect During an Initial Clinical Trial Review
An initial clinical trial review is a practical first step for patients who want to know whether one or more research studies may deserve closer evaluation. It is not the same as formal screening, and it is not a promise of eligibility. Its purpose is to organize the available medical information, compare key facts with current protocols, and identify the most appropriate next question.
Knowing what to expect can make the process more efficient and less stressful.
Key Takeaways
- The initial review looks for possible alignment between the patient's records and a study's major requirements.
- Complete, current records make the review more meaningful.
- A possible match still requires protocol-specific screening, consent, tests, and investigator confirmation.
- Trial status and available slots can change during the review process.
- The research team may need to coordinate with the treating physician to clarify medical history or plan next steps.
Step 1: The inquiry
The process usually begins when a patient, caregiver, or referring physician contacts the research site. Basic information may include the diagnosis, age, location, current treating physician, treatment history, and reason for exploring a trial now.
Use the site's secure process for submitting medical information. A short online form may begin the conversation, but the team will often need supporting records before it can evaluate a protocol responsibly.
Step 2: Record collection
The exact documents depend on the cancer and study. Commonly requested information includes:
- •Recent oncology notes and a concise treatment history
- •Pathology and surgical reports
- •Imaging reports and, when required, image files
- •Laboratory results
- •Biomarker, molecular profiling, or next-generation sequencing reports
- •Current medication list and relevant medical conditions
- •Prior radiation or procedure details
- •Information about performance status or daily functioning
Step 3: Preliminary protocol comparison
A trained research professional compares the records with the major inclusion and exclusion criteria of potentially relevant protocols. The review may consider cancer type, disease stage, measurable disease, prior lines of therapy, required biomarkers, organ function, other diagnoses, medications, and timing since a previous treatment.
Some criteria cannot be evaluated from records alone. A study may require a fresh biopsy, central laboratory confirmation, a specific washout period, additional imaging, or tests performed within a defined window. The principal investigator or another qualified investigator provides medical judgment as appropriate.
The result of this step may be: • A study appears potentially relevant and more information is needed. • No current study appears suitable based on the available information. • The timing is not right, but the patient may be reconsidered if circumstances change. • The team needs clarification from the treating physician or another report.
“Potentially relevant†is intentionally cautious. It is not an eligibility decision.
Step 4: A conversation about the next step
If a study warrants further evaluation, the site may explain its purpose, general schedule, major known requirements, and the formal screening process. The patient should have an opportunity to ask questions and discuss the possibility with the treating oncologist.
Formal screening can begin only through the study's approved process. Informed consent generally occurs before study-specific procedures. Screening may include a medical history, physical examination, laboratory testing, imaging, electrocardiogram, pregnancy testing when applicable, pathology confirmation, or other protocol-defined evaluations.
Why a review may not lead to enrollment
There are many legitimate reasons. A laboratory value may fall outside a required range; a prior treatment may conflict with the protocol; a biomarker may not be confirmed; the study may pause enrollment; a cohort may fill; or the patient and physician may choose another option. These outcomes do not mean that the inquiry was unnecessary. A careful review can still clarify which questions matter and prevent avoidable travel or procedures.
How to prepare
Create a one-page treatment timeline, keep digital copies of key reports, and write down your questions. Tell the site about upcoming appointments or treatment decisions that affect timing. Do not stop or delay prescribed treatment, medications, or procedures to pursue a study without guidance from the treating physician and research investigator.
How our FCTG team can help
Our FCTG initial review is designed to help patients and referring physicians determine whether current oncology protocols may merit deeper evaluation. Our research access team organizes the records, and our physician investigators review the relevant clinical information and protocol requirements. When appropriate and authorized, we coordinate with the treating team to support continuity of care. The process does not guarantee eligibility, enrollment, or access to a study treatment.
Interested in evaluating clinical trial options?
Our medical research team can help review available oncology research options.
Trusted Sources & Further Reading
The information provided by Florida Clinical Trials Group is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical trial availability and eligibility vary by study and participant. Submission of information or completion of an initial review does not guarantee eligibility, enrollment, access to an investigational treatment, safety, or benefit. Patients should discuss all medical care and clinical trial decisions with their treating physician and the qualified research team.
